Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group-Reference-Cited by-同舟云学术

Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group

Published:2019-10-21 Issue:3 Volume:34 Page:953-956
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Eichenauer Dennis A.,Plütschow Annette,Fuchs Michael,Hartmann Sylvia^ORCID,Hansmann Martin-Leo,Böll Boris,von Tresckow Bastian,Borchmann Peter,Engert Andreas

Funder

honoraria from Roche, Takeda and MSD; consulting or advisory role for Amgen, Pfizer, Takeda, MSD; research funding from Novartis, MSD, Takeda; travel funding from MSD, Takeda, Novartis.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0609-3.pdf

Reference14 articles.

1. Eichenauer DA, Engert A. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. Hematol Am Soc Hematol Educ Program. 2017;2017:324–8.

2. Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Boll B, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011;118:4363–5.

3. Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014;32:912–8.

4. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rudiger T, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111:109–11.

5. Eichenauer DA, Goergen H, Plutschow A, Wongso D, Behringer K, Kreissl S, et al. Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. Leukemia. 2016;30:1425–7.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NLPHL: a hummingbird in an owl’s nest;Blood;2023-08-10

2. SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-07

3. Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?;Cancers;2023-06-23

4. Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment;Expert Review of Hematology;2023-06-20

5. Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma;Hematology;2022-12-09